|
|
|
|
Cell therapy has delivered remarkable clinical advances, but today’s manufacturing model remains complex, costly, and difficult to scale. As cell therapy manufacturing reaches its limits, a new model is emerging. Learn how in vivo approaches that harness the body as a bioreactor could expand access and reshape the future.
|
|
|
|
|
Turning the body into a bioreactor could transform how advanced therapies are produced and delivered, but success depends on reaching the right cells with precision. See how lipid nanoparticles, manufacturing science, and biology are converging to overcome biological barriers and improve the targeting of advanced therapies.
|
|
|
|
|
As genomic medicines shift from centralized facilities toward distributed production, manufacturing must serve both population-scale and single-patient therapies. Consistent processes, standardization, and updated regulatory and testing approaches become central to preserving safety and quality across settings.
|
|
|